Back to All Events

London Session 1: Platforms for translating research

  • UCL School of Pharmacy 29-39 Brunswick Square London, England, WC1N 1AF United Kingdom (map)

The Science Innovation Union is offering a groundbreaking bio-entrepreneurship course aimed directly at the UK’s top scientists and budding entrepreneurs. The programme consists of a series of four exciting sessions lead by high profile leading academics and industry experts. Head to our website to sign up now! http://science-union.org/siu360-application

Links to other three session in the SIU360 series:
Session 2: https://www.facebook.com/events/549654898557804/
Session 3: https://www.facebook.com/events/1653754461601574/
Session 4: https://www.facebook.com/events/104791129993224/

Session 1: Platforms for translating research.
For many scientists, translating research means publishing their work in a journal. These publications are critical in advancing our knowledge, however, a non-scientist audience would find it difficult to interpret these findings, and may therefore be excluded from the advancements scientist are achieving, which may be directly linked to the benefit of the public! In this session, the focus will be held on finding appropriate platforms for getting research known to the public. What organised events exist for bringing ideas forward? How to portray research so that it makes sense to a non-scientist? What are the best ways for exposing science to gain the largest impact? 

Speaker: Dr Amir Gander is the lead individual for Tissue Access for Patient Benefit (TAPb), a UCL initiative to bring surplus human tissue from surgery and biobanks to researchers across UK and internationally. Amir was involved with quality management and regulations and also specialised in the development of bench scale drug fermentation techniques to large production scales at a leading pharmaceutical production plant. TAPb has established a network of researchers interested in tissue from specific disease pathways. In collaboration with the state-of-the-art biobank at the Royal Free Hospital London, they have started to supply tissue (with clinical information) to a number of research companies and have strong ties with public and private sector researchers.